{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:50:33Z","timestamp":1789901433276,"version":"4.0.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background and Purpose\u2014<\/jats:italic>\n            <\/jats:bold>\n            The efficacy of the antiplatelet agent triflusal for prevention of vascular events after stroke has been reported in a pilot study. However, there is a need to confirm those results in a larger study.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods\u2014<\/jats:italic>\n            <\/jats:bold>\n            We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg\/d) versus aspirin (325 mg\/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP]). We assessed a combined end point (incidence of nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death) as well as the incidence of these events separately and the incidence of major hemorrhage.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            Of 2113 patients, 1058 received triflusal and 1055 aspirin. The mean follow-up period was 30.1 months. The incidence of combined end point (13.1% for triflusal, 12.4% for aspirin) as well the survival analysis (hazard ratio [HR] for triflusal versus aspirin, 1.09; 95% CI, 0.85 to 1.38) showed no differences between groups. The incidence of nonfatal stroke (HR, 1.09; 95% CI, 0.82 to 1.44), nonfatal acute myocardial infarction (HR, 0.95; 95% CI, 0.46 to 1.98,) and vascular death (HR, 1.22; 95% CI, 0.75 to 1.96) was also similar. A significantly higher incidence of major hemorrhages in the aspirin group was recorded (HR, 0.48; 95% CI, 0.28 to 0.82). The overall incidence of hemorrhage was significantly lower in the triflusal group (16.7% versus 25.2%) (odds ratio, 0.76; 95% CI, 0.67 to 0.86;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001).\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            This study failed to show significantly superior efficacy of triflusal over aspirin in the long-term prevention of vascular events after stroke, but triflusal was associated with a significantly lower rate of hemorrhagic complications.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000063141.24491.50","type":"journal-article","created":{"date-parts":[[2003,4,3]],"date-time":"2003-04-03T21:47:26Z","timestamp":1049406446000},"page":"840-848","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":107,"title":["Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction"],"prefix":"10.1161","volume":"34","author":[{"given":"Jordi","family":"Mati\u0301as-Guiu","sequence":"first","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301 M.","family":"Ferro","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301","family":"Alvarez-Sabi\u0301n","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Torres","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dolores","family":"Jime\u0301nez","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Lago","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Melo","sequence":"additional","affiliation":[{"name":"From the Service of Neurology, Hospital General Universitario de Alicante, Alicante, Spain (J.M-G.); Department of Neurology, Hospital Santa Maria, Lisbon, Portugal (J.M.F., T.M.); Cerebrovascular Unit, Service of Neurology, Hospital General i Universitari Vall d\u2019Hebron, Barcelona, Spain (J.A-S.); Biostatistics and Epidemiology Laboratory, Autonomous University of Barcelona, Barcelona, Spain (F.T.); Service of Neurology, Hospital Universitario Virgen de Valme, Sevilla, Spain (M.D.J.); and Service of..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.31.7.1779"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.15.1667"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00308-5"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00193701"},{"key":"e_1_3_2_6_2","first-page":"155","volume":"284","year":"1986","unstructured":"Garc\u00eda-Rafanell J, Ramis J, G\u00f3mez L, Forn J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther. 1986; 284: 155\u2013165.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_3_2_7_2","first-page":"753","volume":"55","year":"1999","unstructured":"Fernandez de Arriba A, Cavalcanti F, Miralles A, Bayon Y, Alonso A, Merlos M, Garcia-Rafanell J, Forn J. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol. 1999; 55: 753\u2013760.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00707.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000175892"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059456"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1874"},{"key":"e_1_3_2_12_2","first-page":"57","volume":"15","year":"1995","unstructured":"Auteri A, Angaroni A, Borgatti E, Catalano M, De Vizzi GB, Forconi S, Fossati L, Girardello R, Ambrosoli L, Poli A, Di Perri T. Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo. Int J Clin Pharmacol Res. 1995; 15: 57\u201363.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_3_2_13_2","first-page":"269","volume":"91","year":"1991","unstructured":"Putz P, Buyse H, Delvaux D, Kutnowski M, Demulder A, Dumont N, Lavenne E, Claes R, Rosillon D. Triflusal versus acetylsalicylic acid: a double-blind study for the prophylaxis of deep vein thrombosis after hip surgery. Acta Chir Bel. 1991; 91: 269\u2013276.","journal-title":"Acta Chir Bel"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006059101900509"},{"key":"e_1_3_2_15_2","first-page":"1669","volume":"25","year":"1997","unstructured":"Matias-Guiu J, Alvarez-Sabin J, Codina A. Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease [in Spanish]. Rev Neurol. 1997; 25: 1669\u20131672.","journal-title":"Rev Neurol"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780010204"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.12.1044"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251801"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.8.3.324036"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197810262991714"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.14.1.6401878"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.18.2.2882626"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.16.3.2860740"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.16.3.2988158"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.21.8.2202093"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92327-1"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908243210804"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1.300"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000016089"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.102.10.1193"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.2.197"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.11.1248"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7270.1183"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92233-R"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921040-00007"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198907203210301"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855060-00011"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03539-X"},{"key":"e_1_4_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_4_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.2.197"},{"key":"e_1_4_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.12.1549"},{"key":"e_1_4_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.103.2.201"},{"key":"e_1_4_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011258"},{"key":"e_1_4_3_2_7_2","unstructured":"Gorelick PB Richardson D AASPS Investigators. African American Antiplatelet Stroke Prevention Study (AAASPS): Main phase efficacy and safety results. Presented at the 28th International Stroke Conference. Phoenix Arizona February 12\u201315 2003."},{"key":"e_1_4_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)00076-2"},{"key":"e_1_4_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_4_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11469-3"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000063141.24491.50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T20:41:42Z","timestamp":1715546502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000063141.24491.50"}},"subtitle":["The TACIP Study: A Randomized, Double-Blind, Multicenter Trial"],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1161\/01.STR.0000063141.24491.50"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000063141.24491.50","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"2002-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}